Assembly Biosciences Inc, formerly Ventrus Biosciences, Inc. is a development-stage specialty pharmaceutical company. The Company is focused on the development of late-stage and pre-clinical prescription drugs and biologics, for gastrointestinal disorders. The Company�s product portfolio consists of two late stage assets: VEN 307 (topical diltiazem) for relief from pain associated with anal fissures and VEN 308 (topical phenylephrine) for the treatment of fecal incontinence. The Company also is developing a colonic delivery mechanism (VEN 310), which is a PH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules and other treatments precisely to the colon. In addition to VEN 307, VEN 308 and VEN 310, the Company intends to pursue the in-licensing and acquisition of other development stage, as well as pre-clinical assets.